Roche Convinces UK NICE On Cost-Benefit Of RoActemra For Giant Cell Arteritis
Executive Summary
After an initial rejection, Roche's IL-6 drug RoActemra has received support from the UK's health technology assessment body to treat giant cell arteritis in a subset of patients, provided the treatment with the drug is permitted for one year at the most.